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INTRODUCTION
Following the classification of the Coronavirus disease (COVID-19) as a pandemic by the World
Health Organization (WHO), countries were encouraged to implement urgent and aggressive
actions to change the course of the disease spread while also protecting the physical and mental
health and well-being of all people. The challenges and solutions of providing prevention,
treatment, and care for those affected with issues related to substance use and addictive
behaviors are still being discussed by the global community. Several international documents
have been developed for service providers and public health professionals working in the field
of addiction medicine in the context of the pandemic (1–3), however, less is known about
country-level responses. In the current paper we, as individual members of the Network of Early
Career Professionals working in Addiction Medicine (NECPAM), discuss emerging country-level
guidelines developed in the 6 months following the outbreak.
We identified a number of pertinent, country-level documents in the 17 countries represented
here and we summarized country-level briefing notes, practice documents, guidelines, discussion
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papers and other documents containing recommendations on
prevention, harm reduction, treatment, and care for people
who use drugs (PWUD). Documents were identified in 12 out
of the 17 countries. These documents are summarized and
charted in Table 1. Additionally, several documents were under
development at the time of our exercise in the Netherlands,
Slovenia, and Paraguay and have not been included in this
work. No specific documents or intentions to develop any were
identified in Egypt, Uganda, or South Africa. Below we provide a
summary of the identified documents.
Documents developed in Indonesia (4), Italy (5), and Nepal
(6) discuss the use of personal and protective equipment
(PPE). Malaysian (7), Moroccan (8), New Zealand (9–11),
and Australian (12) organizations published documents
which outlined risk assessment and mitigation practices.
Documents in India (13), Malaysia (7), and Thailand (14, 15)
discussed reducing admission of patients. Documents in
India (16), Indonesia (17), and Japan (18) outlined strategies
for maintaining physical distance in clinics and Standard
Operating Procedures (SOP) were developed for isolation units
in Ireland (19).
Italian (20) and Thai (15) documents discussed reducing
addiction services and limiting group meetings. Documents in
France (21), India (13), Italy (20), Ireland (19), Japan (22),
Malaysia (7), New Zealand (11), and Thailand (15) advocated
for the increased use of telemedicine to address the reduction
in services.
Documents published in India (23) and Thailand (24)
addressed substance withdrawal. The Thai document included
strategies for the management of alcohol withdrawal that may
have occurred due to local restrictions on alcohol sales. In Japan
(22), there were discussions regarding the potential increase in
the use of the internet, gambling, gaming, and higher prevalence
of drinking at home during the COVID-19 pandemic.
Documents in France (21), Japan (25), and Ireland (26)
described emerging practices of expedited access to opioid
agonist maintenance treatment (OAMT). Documents in Ireland
(26), India (23), Italy (20), Japan (25), Malaysia (7), Morocco
(8), Nepal (6), and New Zealand (11) advocated for increased
take-home doses (TADs) of OAMT. SOPs for buprenorphine-
naloxone TADs in a hospital context have been developed
in India (27) and documents in Indonesia (17), Nepal (6),
Malaysia (7), and Italy (5) advocated for increased TADs of
OAMT to 7 days, 14 days and 1 month, respectively. An Irish
document (26) advocated for prescriptions for naloxone for all
new OAMT patients and changes in the naloxone administration
procedure (move toward intramuscular injection and chest
compression in the absence of specialized equipment during
opioid overdose interventions).
Guidelines, SOPs and recommendations in Nepal (6), Ireland
(28, 29), and France (21), respectively, have also advocated for
increased access to harm reduction services. In New Zealand,
guidelines addressed practices of adopting a health equity/social
determinant lens, developing culturally and trauma informed
approaches, awareness, and education efforts, development of
self-help resources and the inclusion of people with lived
experience of substance use and gambling into the evaluation of
interventions (10, 11).
DISCUSSION
A range of practices have been suggested at the country-level to
deal with the challenges brought about by the ongoing pandemic.
These include those around mitigating the spread of the corona
virus, managing the risks associated with lockdown policies and
changing trends in substance use and addictive behaviors.
In order to limit the spread of COVID-19, guidance has been
drawn up to limit in-personmeetings, physical support meetings,
and contact time with physicians. Guidance suggests that this
be operationalised through shifting services online, increased
availability of TADs of OAMT, increased duration of TADs
and increased availability of naloxone and injecting equipment
allocations. Protocols have also been drawn up for the operation
of clinics and outreach services for patients in isolation.
Several potential negative effects associated with the pandemic
and resulting lockdown procedures have been identified which
may require service adaptions. These include increased risks
of substance withdrawal (30), access to service issues and
potential changes in trends related to gambling, gaming, and
internet related disorders. Several guidance documents discuss
meeting these challenges through increased access to TADs,
expedited access to OAMT and increased availability of online-
based self-help groups and other services (11, 17–30). The
increased commitment to TADs, telemedicine and access to harm
reduction supplies are likely to address several issues brought
about by the pandemic for people who use opioids and/or inject
drugs. However, few documents explicitly discuss the increased
availability of harm reduction supplies (for example, naloxone
and injecting equipment) and service adaptions for people who
use non-opioid drugs and/or engage in addictive behaviors
(such as gambling and gaming) continue to be neglected by
most documents.
There are also concerns regarding the implementation
of COVID-19-related policy documents as a recent global
survey indicates that among 130 countries, 60% reported
disruptions to mental health services for vulnerable people,
67% reported disruptions to counseling and psychotherapy,
35% reported disruptions to emergency interventions, and
30% reported disruptions to access for medications for
mental, neurological, and substance use disorders (31). The
combination of a reduction in the availability of services,
increased reliance on telemedicine, physical distancing protocols,
and travel restrictions may exasperate underlying health
inequities in terms of access to addiction services (31–34).
This seems to disproportionately affect the most marginalized
and socioeconomically disadvantaged patients (32) who may
lack access to internet-enabled devices, sufficient internet, the
necessary private spaces to engage in telemedicine and means of
transport to services.
The lack of representation of country-level documents from
the Americas, Eastern Europe, the Middle East, Africa, and
other regions is a limitation of this paper. Future research
should document emerging practices in additional regions and
monitor and evaluate the implementation of country-level
policies. Country-level documents may be useful as they may
allow clinicians to adapt to their given local context. Such
documents should consider best emerging practices as it relates
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TABLE 1 | Country specific COVID-19 guidance documents for clinical practice in addiction medicine.
Country Author Type Topics
India AIIMS (All India institute of medical
sciences, New Delhi
Guidelines • TADs of buprenorphine and methadone (bi weekly or alternate days)
• Take home doses to be managed by “responsible adults”
Basu D, Ghosh A, Subodh BN et al. SOP • Hospital SOP for buprenorphine-naloxone TADs
Indian Psychiatric Society Position
statement,
guidelines
• Warns of potentially increased incidence of AOD withdrawal and associated
complication
• Advocates for seven-day TADs
• Advocates for physical distancing in OAMT clinic
• Discusses supply/travel restrictions and human resource issues
Indian Psychiatric Society and




• Advocates for reducing admissions
• Physical distancing guidelines
• Tobacco use
• Telemedicine for follow up
• Discusses challenges associated with physical distancing in emergency
case management
Indonesia Ministry of Health • Advocates for TADs
• Increased use of telemedicine
• Safety procedures including PPE
Ireland Health Service Executive Guidelines,
guidance
documents, SOPs
• Recommends expedited access to OAMT (using telemedicine where possible)
• Increased TADs
• Increased naloxone availability (all inducted patients to be offered prescription)
• Changes in naloxone administration (preference for IM, chest compressions only
unless specially trained and with special equipment)
• Telemedicine for follow up
• Details procedure for expedited emergency induction
• Standard operating procedure for operating National Drug Treatment Center Pharmacy
OAMT program
• Outlines general procedures for operating NSPs
• Supply management
• Advocates for increased harm reduction
• Discusses challenges associated with human resources
• Recommendations for storage and handling of prescription medication
• Recommendations for conducting addiction telemedicine consultations
Italy Federazione Italiana Operatori




• Detailed hygiene practices
• Reduction of services
• Suspension of groups (unless physical distancing is possible)
• Promotion of telehealth
• TADs OAMT (1 month)
• Reduction of urine testing
• Care with breathalyzers
• Guidelines for service delivery in prison
• Increased availability of extended-release preparations
France Ministères des Solidarités et de la
Santé
Recommendations • Advocates for easier access to OAMT and nicotine replacement therapies (NRTs)
• Advocates for maintaining communication with patients using telemedicine and
reserve in-person meetings for emergencies
• Improved prescription renewal procedures
Japan Ministry of Health, Labor, and
Welfare.
Policy • Procedures for expedited emergency induction
• Increased TADs
• Physical distancing
Japanese Medical Society of
Alcohol and Addiction Studies
Guidelines • Warns of overuse of the internet, gambling, gaming and drinking at home
The Japanese Society of Psychiatry
and Neurology
Guideline • Use of online-based self-help groups




• Mental health and psychosocial support in COVID-19:
1) For general population
2) For healthcare workers
3) For team leaders in health facilities
4) For care providers for children
5) For older adults, care providers, people with underlying health conditions
• COVID-19 Management Guideline for special settings, including prisons, lockup and
detection camps
(Continued)
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TABLE 1 | Continued
Country Author Type Topics
National Anti-Drugs Agency Guidance
document
• Use of online- and telephone - based counseling
Morocco Moroccan Addictology Association Guidelines • Advocates for TADs, home deliveries and take home naloxone
• Warns of particular interactions between methadone and hydroxychloroquine and
chloroquine- QT interval
• Vigilant stock management of methadone
• General PPE and risk reduction/control measures
Nepal Ministry of Health and Population
and National Center of AIDS & STD
Control
Guidelines • Provisions for OAMT and other harm reduction services
• Guidance for PWID harm reduction program including TADs for OAMT (upto 7 days),
family involvement, social support unit and NSP.
• Recommendation for continuing HIV services
• PPE recommendations in ART centers and OAMT clinics
• Guidelines for community-based care and community care center for PLHIV
New Zealand Ministry of Health Guidelines and
Resources
• Advocates for linking of employment, addiction and mental health services
• Advocates for addressing the housing needs of people with severe mental health and
substance harm issues
• Advocates for harm reduction approaches for substance use and gambling
• Promotes education and raising awareness
• Promotes mental health and addiction telemedicine support
• Promotes access to self-help tools for substance use and gambling
• Promotes inclusion of people with lived experiences of addiction in service design
• Advocates for Maori specialist services and increased primary care services
The Royal Australian and New
Zealand College of Psychiatrists
Guideline and
resources
• Advocates for increased TADs and reduced supervised dosing
• Provides risk assessment and mitigation procedures for TADs
• Outlines medication management procedures for ‘isolated’ patients
• Advocates for buprenorphine depot
• Advocates for telehealth
Thailand Department of Medical Services,
Ministry of Public Health
Guidance
document
• Practical guide for admission rehabilitation and follow-up
• Individual treatment only; limit group treatment
• Decreased admissions except for emergency (e.g. delirium tremens)
• Use of telemedicine
• Use of public health volunteers




• Limit admissions to severe emergency cases and advocate for screening for COVID-19
• Provide information regarding COVID-19 to patients
• Limit family visit and group activity
• Physical distancing in treatment centers




• Recommendations concerning alcohol withdrawal for physicians, nurses, and public
health personnel
to issues surrounding a wide range of substances, addictive
behaviors, harm reduction, and health inequities exasperated by
the pandemic and restrictions.
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